Accomplished executive will strengthen computational biology capabilities

Cambridge, MA - January 31, 2007 - Codon Devices, the Constructive Biology™ Company, announced today that it has appointed Stan Letovsky, PhD to the newly created position of Executive Director of Bioinformatics and Information Technology.

Dr. Letovsky brings 20 years of experience in industrial and academic bioinformatics. He was most recently Senior Director of Computational Sciences at Millennium Pharmaceuticals, where he led a team of computational biologists, computational chemists, biostatisticians and software engineers supporting the R&D organization. Prior to his role at Millennium, Dr. Letovsky led Monsanto’s global bioinformatics organization, including teams in St. Louis, Cambridge, and Bangalore. Dr. Letovsky also served as Associate Professor at Johns Hopkins Medical Institute where he directed the Genome Database Project (GDB). He holds a B.A. from Cornell University and a PhD from Yale University in Artificial Intelligence. In addition, he conducted post doctorate research in Machine Learning at Carnegie Mellon University. Dr. Letovsky has served on the Advisory Committees of numerous NIH-sponsored model organism database initiatives. He is currently an adjunct faculty member at Boston University’s Bioinformatics program.

Craig Muir, Senior Vice President of Technical Operations said, “Building world-class bioinformatics capabilities is critical to making our Constructive Biology™ vision a reality. Stan’s broad and deep leadership experience in the pharmaceutical and agriculture industries will be vital as we continue to scale our proprietary, industry-leading BioFAB™ technology and further develop our protein engineering platforms.”

About Codon Devices
Codon Devices, based in Cambridge, MA, was founded in 2004 to pioneer commercial applications of Synthetic Biology. In June, 2005, Codon Devices raised $13M in a Series A financing involving Flagship Ventures, Kleiner Perkins, Alloy Ventures, and Mr. Vinod Khosla. In December 2006, the Company closed a $20M Series B financing led by Highland Capital Partners, with all previous investors participating. Codon Devices' distinguished founding scientific advisory board (SAB) is comprised of top scientists in the field, including Chairman George Church, Harvard Medical School, David Baker, Howard Hughes Medical Institute Investigator at the University of Washington; Jim Collins, Boston University; Michael Elowitz, California Institute of Technology; Drew Endy, Massachusetts Institute of Technology; Michael Hunkapiller, Alloy Ventures; Joseph Jacobson, Massachusetts Institute of Technology; Jay Keasling, UC Berkeley; Paul Modrich, Howard Hughes Medical Institute Investigator at Duke University; Christina Smolke, California Institute of Technology; Ron Weiss, Princeton University; and David Liu, Harvard University.

Codon Devices' proprietary BioFAB™production platform is expected to enable large-scale biological research; engineered cells that produce novel pharmaceuticals; improved vaccines; agricultural products; and biorefineries for the production of industrial chemicals and energy. The BioFAB™platform is expected to accurately synthesize kilobase- to megabase-length genetic code orders of magnitude more rapidly and less expensively than currently available technology. The company has internally developed and licensed-in intellectual property related to the efficient synthesis of DNA code. In addition, Codon Devices has developed proprietary designs and production processes related to the BioFAB™. The company's early commercial focus is on providing engineered devices for molecular biology research and engineered biotherapeutics.